Patient Selection. Participants will be breast cancer patients with stage I-III histologically confirmed diagnosis.
Patient Selection. Physician is solely responsible for identification and selection of the patient to be treated with the Investigational Product. Physician certifies that the selection of the patient is under his or her personal responsibility and acknowledges that neither the Institution nor Ultragenyx or any other third party will have had any involvement in or influence over the selection process. Therefore, the Parties agree that Ultragenyx will have no involvement in the treatment of the patient(s) and will have no responsibility or liability for this treatment or any consequences thereof. The Physician explained to the patient the scope of the compassionate use treatment in specific with regard to the Investigational Product and the patient acknowledged and agreed to the scope of such treatment.
b.1 The Physician will monitor the patient and maintain active communication with the patient, Ultragenyx and the Institution to meet its obligations in accordance with the present Agreement.
Patient Selection. If you are obese or have soft or thin skin, medical problems, the wrong idea about what the surgery can do, then liposuction may not be right for you. Liposuction in General: When the surgeon injects the watered-down local anesthesia and epinephrine into the fat, it may lead to fluid overload. You may have a systemic reaction to these medications. You may need more treatment and spend more time in the hospital. Damage to Structures: You may get injured around the area where the liposuction is done. The surgery may cause problems in your blood vessels and nerves. If you have it done around your belly, the surgery could damage your bowel, bladder, or abs. If you have it done around your chest, one of your lungs could collapse.
Patient Selection. Patients at least 4 years of age with PAH-deficient hyperphenylalaninemia were recruited from a single center to evaluate their BH4 responsiveness. Patients were excluded if they were pregnant or breastfeeding, were previously determined to be BH4 responsive, or had taken biopterin in the previous 8 weeks. Informed consent was obtained for all participants. This protocol was approved by the Emory University Institutional Review Board.
Patient Selection. Twenty-six patients who received liver transplants because of HCV-related disease from July 1991 to No- vember 1995 were identified through our transplant database (Ta- ble 1). Twenty-one biopsies were performed for investigation of an abnormal alanine aminotransferase level, and 5 for routine post-OLT follow-up. A liver biopsy performed within the first month after OLT was considered an early biopsy; all others were considered late biopsies. Pathologic Interpretation.—Six weeks before initiation of the study, 2 experienced hepatopathologists (T.G. and X.X.) reviewed definitions of each pathologic feature by evaluating typical ex- amples of recurrent hepatitis C infection and acute cellular rejec- tion. Both pathologists had approximately 8 to 10 years of train- ing and experience. Each biopsy specimen was read blindly by the first pathologist (T.G.). Six weeks later, these specimens were read again blindly by both pathologists. The order in which the biopsy specimens were read was randomly assigned. An overall pathologic diagnosis was made by choosing one of the following categories: (1) recurrent chronic hepatitis C, (2) acute cellular re- jection, (3) both, or (4) normal. Clinical Data.—For the purpose of this study, an episode of acute cellular rejection was defined as agreement between pa- thologists on the final pathologic diagnosis of acute cellular re- jection and a response to antirejection therapy (normalization or near normalization of liver enzymes). An episode of recurrent hepatitis C infection was defined as agreement between pathol- ogists on the pathologic diagnosis, no response to antirejection therapy, and the establishment of chronic hepatitis C infection in the follow-up biopsy specimens and clinical data. Clinical data and follow-up data were available from the transplant database and review of medical records. The HCV RNA was determined by polymerase chain reaction (Amplicore HCV Monitor, Roche Diagnostic Systems, Branchburg, NJ) with a threshold for de- tectability of 1000 copies/mL or by a branch DNA method (Quantiplex 1.0, Chiron Corporation, Emeryville, Calif) with a Characteristics No. (%)
Patient Selection. In selecting patients with whom to enter into a direct 12 primary care agreement, a health care provider may not discriminate on the basis 13 of age, citizenship status, color, disability, gender or gender identity, genetic 14 information, health status, existence of a preexisting medical condition, national 15 origin, race, religion, sex, sexual orientation, or any other protected class. A health 16 care provider may base subscription fees under a direct primary care agreement on 17 age.
Patient Selection. In selecting patients with whom to enter into a direct primary care agreement, a health care provider may not discriminate on the basis of existence of a preexisting medical condition or health sta- tus or a basis specified in s. 51.90, except that a health care provider is not required to enter into an agreement with a patient whose medical condition is such that the health care provider is unable to provide the appropriate level and type of health care services. A health care provider may base subscription fees under a direct pri- xxxx care agreement on age.
Patient Selection. All hospitalizations with a supplementary classification of external causes of injury and poisoning code for motorcycle-related crashes (codes E810-E825, where fourth digits two and three identify the injured person(s) as the motorcyclist and/or passenger on motorcycle from the International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM]) were included in the analysis (Appendix 1). DATA SOURCE Data from the HCUP NIS for the years 2005 through 2007 was analyzed for this study. The NIS, conducted annually by the Agency for Healthcare Research and Quality (AHRQ), is a nationally representative sample survey of US community hospitals that contains clinical and resource use information for approximately eight million inpatient hospital stays from over 1,000 hospitals in 40 states. The NIS is a stratified, single-stage cluster sample in which a stratified random sample of hospitals that approximates 20% of all US community hospitals, for which all discharges are included in the final sample. The HCUP application and data use agreement are required to purchase NIS datasets. The data use agreement binds the user to the data protections put forth in the Health Insurance Portability and Accountability Act (HIPAA). The NIS is provided on two CD-ROMs that include fixed-width ASCII formatted files. The first CD-ROM contains the Inpatient Core and Hospital Weights files. The Inpatient Core file is an inpatient discharge-level file containing data for 100% of the discharges from the sample of hospitals in participating states; the unit of observation is the inpatient stay record. The Hospital Weights file contains one observation for each hospital included in the NIS with weight, variance and linkage data elements; the unit of observation is the hospital. The second CD-ROM contains the Disease Severity Measures and Diagnosis and Procedure Groups File; however, these sources of data were not used in this analysis. The Cost-to-Charge Ratio (CCR) files contain hospital-specific cost-to-charge ratios based on all-payer inpatient costs obtained from hospital accounting reports collected by the Centers for Medicare and Medicaid Services (CMS). The CCR files are required to transform charge information within the Inpatient Core file, representing the amount that hospitals billed for services, into costs that reflect how much hospital services cost or the specific amounts that hospitals received in payment. Upon merging the CCR files with total char...
Patient Selection. Immunocompetent, non-pregnant individuals, 4 years of age or older, without complicated comorbid conditions, such as chronic lung or heart disease, will be eligible for rapid antigen testing for strep throat. The patient’s history of present illness and a determination of present illness suggestive of Group A beta-hemolytic streptococcus (GABHS) shall be documented on an “Acute Pharyngitis Evaluation” form. Rapid antigen strep testing will be limited to patients with two to four of the Centor Sore Throat Criteria. Fever > 101o F Tonsillar exudates No cough Tender enlarged cervical nodes Determining the presence of the Centor criteria will require the pharmacist to visually examine the patient’s throat, measure temperature, and palpate the cervical node in the patient’s neck.
Patient Selection. This study was conducted in accordance with the guidelines and after approval of our institutional review board. Informed consent was waived in accordance with local legislation regarding retro- spective studies. We identified all consecutive patients with sub- arachnoid hemorrhage from August 2007 to March 2008 at our department who fulfilled the following inclusion criteria: 1) the CTP acquisition included the circle of Xxxxxx region, 2) the corre- sponding CTA was acquired during the arterial phase with con-
